AU2003250831A1 - Use of hec1 antagonists in the treatment of proliferative disorders and cancer - Google Patents
Use of hec1 antagonists in the treatment of proliferative disorders and cancerInfo
- Publication number
- AU2003250831A1 AU2003250831A1 AU2003250831A AU2003250831A AU2003250831A1 AU 2003250831 A1 AU2003250831 A1 AU 2003250831A1 AU 2003250831 A AU2003250831 A AU 2003250831A AU 2003250831 A AU2003250831 A AU 2003250831A AU 2003250831 A1 AU2003250831 A1 AU 2003250831A1
- Authority
- AU
- Australia
- Prior art keywords
- hec1
- antagonists
- cancer
- treatment
- proliferative disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02013006 | 2002-06-12 | ||
| EP02013006.8 | 2002-06-12 | ||
| PCT/EP2003/006205 WO2003105891A2 (en) | 2002-06-12 | 2003-06-12 | Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003250831A1 true AU2003250831A1 (en) | 2003-12-31 |
| AU2003250831A8 AU2003250831A8 (en) | 2003-12-31 |
Family
ID=29724387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003250831A Abandoned AU2003250831A1 (en) | 2002-06-12 | 2003-06-12 | Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1519736A2 (en) |
| AU (1) | AU2003250831A1 (en) |
| WO (1) | WO2003105891A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4761389B2 (en) | 2004-04-09 | 2011-08-31 | 株式会社ジーンケア研究所 | Cancer cell-specific apoptosis inducer targeting genes related to chromosome stabilization |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| WO2007075206A2 (en) * | 2005-09-30 | 2007-07-05 | The Regents Of The University Of California | Satb1: a determinant of morphogenesis and tumor metastatis |
| RU2486195C2 (en) | 2007-08-20 | 2013-06-27 | Онкотерапи Сайенс, Инк. | Cdca1 peptide and pharmaceutical drug containing it |
| TWI526219B (en) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Cdca1 epitope peptides and vaccines containing the same |
| BR112012023355A2 (en) | 2010-03-17 | 2016-05-31 | Taivex Therapeutics Inc | compound, pharmaceutical composition and method of disruption of nek2 / hec1 interaction |
| US11071736B2 (en) | 2011-11-21 | 2021-07-27 | Taivex Therapeutics Corporation | Modulators of HEC1 activity and methods therefor |
| US9976183B2 (en) * | 2011-11-21 | 2018-05-22 | Taivex Therapeutics Corporation | Biomarkers for cancers responsive to modulators of HEC1 activity |
| TWI640519B (en) | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Modulators of hec1 activity and methods therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6795898A (en) * | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
-
2003
- 2003-06-12 EP EP03759949A patent/EP1519736A2/en not_active Withdrawn
- 2003-06-12 AU AU2003250831A patent/AU2003250831A1/en not_active Abandoned
- 2003-06-12 WO PCT/EP2003/006205 patent/WO2003105891A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1519736A2 (en) | 2005-04-06 |
| WO2003105891A3 (en) | 2004-05-06 |
| AU2003250831A8 (en) | 2003-12-31 |
| WO2003105891A2 (en) | 2003-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL151946A0 (en) | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders | |
| HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
| AU2003223380A1 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
| AU2003261100A1 (en) | Devices delivering therapeutic agents and methods regarding the same | |
| IL180278A0 (en) | Fused pyrimidones useful in the treatment and the prevention of cancer | |
| PL369822A1 (en) | Use of endothelin receptor antagonists in the treatment of tumour diseases | |
| AU2003250831A1 (en) | Use of hec1 antagonists in the treatment of proliferative disorders and cancer | |
| GB0212405D0 (en) | Composition and its therapeutic use | |
| AU2003274963A1 (en) | Mda-7 and free radicals in the treatment of cancer | |
| AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases | |
| EP1539100A4 (en) | Composition and methods for the treatment of skin disorders | |
| AU2003271016A1 (en) | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis | |
| AU2003219664A1 (en) | Methods and therapeutic compositions in the treatment of advanced cancer | |
| AU2004281077A1 (en) | Methods and agents for the treatment of cancer | |
| AU2003244437A1 (en) | Quinoxalinones and their use especially in the treatment of cardiovascular diseases | |
| AU2002328173A1 (en) | Omoxin agonists and antagonists for use in the treatment of metabolic disorders | |
| AU2002339682A1 (en) | Emergen agonists and antagonists for use in the treatment of metabolic disorders | |
| AU2003247094A1 (en) | Enhancing the effect of radioimmunotherapy in the treatment of tumors | |
| AU2002363367A1 (en) | Use of endothelin receptor antagonists in the treatment of tumour diseases | |
| AU2003246880A1 (en) | Alkaloid-derived compounds and use thereof in cancer and malaria treatment | |
| AU2002357468A1 (en) | Use of 2-acylindoles in the treatment of tumors | |
| AU2002321764A1 (en) | Genobix agonists and antagonists for use in the treatment of metabolic disorders | |
| AU2002339689A1 (en) | Dexar agonists and antagonists for use in the treatment of metabolic disorders | |
| AU2002339688A1 (en) | Glucoset agonists and antagonists for use in the treatment of metabolic disorders | |
| AU2002339679A1 (en) | Glucomin agonists and antagonists for use in the treatment of metabolic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |